Evidence map›Paper›PMID 42888952›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Integration of neuroimaging signatures of aging and Alzheimer's with fluid biomarkers.

Mitzi M Gonzales, Ngoc Huynh Ho, David H Wang, Tanweer Rashid, Sachintha R Brandigampala, Mengjin Dong, David Martinez, Sokratis Charisis, Timothy J Hohman, Sudha Seshadri and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Mitzi M GonzalesDepartment of Neurology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Ngoc Huynh HoThe Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, The University of Texas Health Science Center, San Antonio, Texas, USA.
David H WangThe Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, The University of Texas Health Science Center, San Antonio, Texas, USA.
Tanweer RashidThe Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, The University of Texas Health Science Center, San Antonio, Texas, USA.
Sachintha R BrandigampalaThe Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, The University of Texas Health Science Center, San Antonio, Texas, USA.
Mengjin DongThe Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, The University of Texas Health Science Center, San Antonio, Texas, USA.
David MartinezThe Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, The University of Texas Health Science Center, San Antonio, Texas, USA.
Sokratis CharisisThe Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, The University of Texas Health Science Center, San Antonio, Texas, USA.
Timothy J HohmanDepartment of Neurology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Sudha SeshadriThe Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, The University of Texas Health Science Center, San Antonio, Texas, USA.
Christos DavatzikosArtificial Intelligence in Biomedical Imaging Laboratory (AIBIL), Center for AI and Data Science for Integrated Diagnostics (AI2D), Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Gladys MaestreDepartments of Neurosciences and Human Genetics, University of Texas Rio Valley Grande, Brownsville, Texas, USA.
Tiffany F KautzThe Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, The University of Texas Health Science Center, San Antonio, Texas, USA.
Ashley LaRocheThe Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, The University of Texas Health Science Center, San Antonio, Texas, USA.
Vanessa M YoungThe Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, The University of Texas Health Science Center, San Antonio, Texas, USA.
Anna Campbell SullivanThe Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, The University of Texas Health Science Center, San Antonio, Texas, USA.
Kristine YaffeDepartments of Psychiatry, Neurology, and Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Jon B ToledoNantz National Alzheimer Center, Stanley Appel Department of Neurology, Houston Methodist Hospital, Houston, Texas, USA.
Alzheimer's Disease Neuroimaging InitiativeHABS‐HD Study Team
Mohamad HabesThe Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, The University of Texas Health Science Center, San Antonio, Texas, USA.

Funding

South Texas Alzheimer's Disease Research CenterP30AG066546 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Sudha Seshadri · 2021 to 2026
$24.0M
TRAINING GRANT ON THE BIOLOGY OF AGINGT32AG021890 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Erzsebet Kokovay, JAMES FLOYD NELSON · 2003 to 2026
$11.4M
Cerebral tau deposition and comorbid cerebrovascular disease across the Alzheimer's disease continuum in Mexican AmericansR01AG085571 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GONZALES, MITZI MICHELLE, HABES, MOHAMAD · 2024 to 2025
$5.7M
Cognitively Healthy Nonagenarians in the Cross Cohort Collaboration (CCC)R01AG059421 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Stephanie Anne-Carine Debette, Carole Dufouil · 2026 to 2026
$4.7M
Resource Core 3 (RC3), Data ScienceP30AG094848 · NIA · CEDARS-SINAI MEDICAL CENTER · PI Susan Cheng · 2025 to 2026
$4.0M
Characterizing Older Mexican (American) Participation in Activity Digitally, Reliably, and Ecologically with the CART Platform (COMPADRE CART): Implications for Cognition and ADRDR01AG077472 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Zachary Beattie, Mitzi Michelle Gonzales · 2022 to 2026
$3.8M
Multiethnic machine learning brain signatures of ADRDR01AG080821 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HABES, MOHAMAD · 2022 to 2025
$2.9M
Vascular Imaging Biomarker Relationships to Alzheimer’s disease (VIBRA)R01AG083865 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Mohamad Habes, Timothy M. Hughes · 2024 to 2026
$2.3M
Alzheimer's AssociationDKR Texas Alzheimer's Initiative T32AG021890NIA NIH HHS P30 AG066546NIA NIH HHS P30 AG094848NIA NIH HHS R01 AG059421NIA NIH HHS R01 AG077472NIA NIH HHS R01 AG080821NIA NIH HHS R01 AG083865NIA NIH HHS R01 AG085571NIA NIH HHS R01AG085571 R01AG077472 P30AG094848 P30AG066546 R01AG083865 R01AG080821 R01AG059421NIA NIH HHS T32 AG021890Texas Alzheimer's Research and Care Consortium Investigator Grant ProgramTexas Council on Alzheimer's Disease and Related Disorders
6 · The paper itself

Abstract

introductionMachine learning algorithms applied to neuroimaging may aid diagnosis and disease monitoring. This study aimed to derive neuroimaging signatures of brain aging (Spatial Pattern of Atrophy for Recognition-Brain Age [SPARE-BA]) and Alzheimer's disease (SPARE-AD) in a diverse sample and to examine their associations with plasma biomarkers, diagnosis, and disease progression.

methodsSPARE-BA and SPARE-AD were calculated using T1-images from 1297 participants without dementia. Associations between neuroimaging signatures and plasma biomarkers were assessed with partial correlations. Logistic regression and cox proportional hazard models evaluated diagnostic accuracy and clinical progression.

resultsSPARE-AD displayed the strongest association with plasma phosphorylated tau 217, whereas SPARE-BA correlated most strongly with plasma neurofilament light. The combination of neuroimaging signatures with plasma biomarkers achieved the highest diagnostic discriminability and strongest associations with clinical progression. DISCUSSION: Neuroimaging signatures of aging and Alzheimer's disease display distinct associations with plasma biomarkers. Neuroimaging signatures combined with plasma biomarkers may improve the detection and prediction of cognitive impairment.

Indexed as

AgingAlzheimer DiseaseBiomarkersBrainNeuroimagingAgedAged, 80 and overAtrophyDisease ProgressionFemaleHumansMachine LearningMagnetic Resonance ImagingMaleNeurofilament Proteinstau ProteinsBiomarkersneurofilament protein LNeurofilament Proteinstau ProteinsAlzheimer's diseasecognitive impairmentdiagnosismachine learningneuroimagingplasma biomarkersprognosis

Identifiers

PMID42888952
PMCPMC13675842

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.